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Background: Phosphatase and tensin (PTEN) gene is a tumor suppressor gene on chromosome 10q23 that is 
composed of 11 exons. Several studies have shown that loss of PTEN function is a common occurrence in 
breast cancer in particular in triple negative type, and it is significantly associated with age and higher stage of 
cancer. In this study, the expression of this gene in malignant breast cancer tissue samples and their correlation 
with clinicopathologic parameters was studied. 
Methods: In this retrospective study, 65 malignant tissue samples were chosen for immunohistochemistry 
(IHC) test. Other information about clinicopathologic features were collected from pathology reports and 
patients’ medical records. IHC on the selected paraffin blocks was performed, and the collected data were 
analyzed using SPSS software and chi-square test. P < 0.0500 was considered statistically significant. 
Results: PTEN expression rate in malignant breast tissue was 50.8% of the cases (33 out of 65 samples). Lack 
of PTEN expression had significant correlation with involvement of the lymph node sent by the sample, 
vascular or perineural invasion, metastasis and chemotherapy background, spontaneous malignancy presence, 
familial history, negative progesterone receptor, negative estrogen receptor, and positive her2/neu. No 
relationship was observed between the expression of PTEN with patients’ age, tumor size, age group of the 
patients after categorization into two groups of under 50 years and over 50 years, lesion location (left or right 
breast), and tumor grade. 
Conclusions: The results showed PTEN loss as a frequent event in breast cancer that is closely associated with 
progression and poor prognosis. PTEN loss might predict more aggressive behavior and worse outcomes in 
patients with breast cancer. 
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Introduction 
Phosphatase and tensin (PTEN) gene is a tumor 
suppressor gene on chromosome 10q23 that is composed 
of 11 exons (1). PTEN homolog on chromosome 10 is 
one of the most common tumor suppressors that are 
mutated in human cancers. PTEN catalyzes converting 
phosphatidylinositol (3,4,5)-trisphosphate into 
phosphatidylinositol (4,5)-bisphosphate lipid membrane 
and is the main mediator of AKT/protein kinase B 
pathway. Inherited PTEN mutations increase 
susceptibility to Cowden syndrome (syndrome with 
autosomal dominant inheritance pattern characterized by 
hamartomas, and increased susceptibility to breast cancer 
and thyroid cancer), which is associated with 25-50 
percent increase in risk of susceptibility to breast cancer. 
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Furthermore, PTEN somatic mutations are associated with 
different types of cancers in which glioblastoma is 
considered as the most common type (2-4). 
Several studies have shown that loss of PTEN 
function is a common occurrence in breast cancer in 
particular in triple negative type, and it is significantly 
associated with age and higher stage of cancer (5,6). 
Furthermore, several studies have found that patients with 
PTEN gene expression are sensitive to the doxorubicin, 
while patients without or with reduced expression of this 
gene are resistant to the doxorubicin (7). Other studies 
stated that loss of PTEN function may be associated with 
resistance to the herceptin (trastuzumab). Herceptin 
(trastuzumab) can lead to improved prognosis in positive 
her2 cancer patients; however, some patients do not 
respond well to this drug or are resistant to it; it is reported 
that lack of PTEN may be responsible for the poor 
response (8,9). Loss of PTEN function has been reported 
in 15-65% of positive her2 breast cancers (10). 
The role of this gene in breast cancer when it is 
next to genes such as BRCA1 and P53 is neglected. 
Recent studies have considered the importance of this 
gene in early diagnosis and treatment of breast cancer, 
especially triple negative types (11). Given the 
importance and prevalence of breast cancer in different 
communities as well as by the importance that the 
expression or non-expression of this gene can be used in 
treatment and prognosis of patients with breast cancer, in 
this study, the expression of this gene in malignant 
breast cancer tissue samples and their correlation with 
clinicopathologic parameters was studied. 
 
Materials and Methods 
This study is a retrospective, descriptive study on 
patients who underwent biopsy or breast surgery during 
2012-2015 (since the early 2012 to the late 2015) in 
Imam Reza Hospital (501 Artesh of Islamic Republic 
of Iran). To do this, referring to the hospital pathology 
ward and examining samples’ registries, all 
pathological reports of the patients in this period 
available in hospital pathology ward were studied, and 
samples prepared from breast tissue were separated. 
Then, data collection form was completed based on the 
information in pathology reports, including patients’ 
age, sex, tumor location, sample size, final diagnosis 
and tumor size, tumor grade, Nottingham score, lymph 
node involvement, and vascular or perineural invasion 
in the case of tumoral tissues. Meanwhile, a number of 
samples were deficient in information that was 
corrected and completed by referring to patients’ 
admission records at the archives and phone call to 
patients. Finally, 188 patients were included in the 
study with 230 samples. Among the samples,  
65 malignant tissue samples were chosen for 
immunohistochemistry (IHC) test. 
IHC on the selected paraffin blocks was performed 
with the help of Professor Kamalian’s Laboratory. The 
specimens were fixed in formalin (10%). Tissue 
passage was performed by tissue processing device, 
and after infiltration of the samples in melted paraffin, 
the samples were embedded in paraffin. 4 µ were 
prepared from all samples with litze microtome. The 
slides containing the samples were stained with 
hematoxylin and eosin; the slides were reviewed by 
two expert pathologists (double-blind). PTEN gene 
expression in samples was performed as follows. 
Temperature and concentrations of antibodies for IHC 
was performed according to the kit protocol, but for 
mask removal of the antigenic characteristics of the 
samples’ areas, the microwave and citrate buffer was 
used at 100 °C for 10 minutes. To inhibit the 
endogenous peroxidase activity, it was placed in 3% 
hydrogen peroxide for 30 minutes and then the slides 
were 5 times washed by phosphate saline buffer. The 
primary antibody (primary specific rabbit monoclonal 
PTEN antibody) Novocastra (Newcastle, UK) was 
dropped on the slides and were washed 3 times with 
phosphate saline buffer and then the secondary 
antibody was used. The slides were washed 3 times by 
phosphate saline buffer to cross to the next stage. 
Streptavidin connected to horseradish peroxidase 
which is capable of emitting diaminobenzidine was 
used to stain the cells, and it was analyzed by an 
optical microscope and the image was taken. The cells 
stained < 10% were considered negative, those with 
more than 10% of brown color were considered 
positive, and taking into account the expression of the 
PTEN, the slides were divided into positive and 
negative degrees. The collected data were analyzed 
using SPSS software (version 23, IBM Corporation, 
Armonk, NY, USA) and chi-square test, and  
P < 0.0500 was considered statistically significant.  
 
Results 
A total of 188 patients (mean age 51.5 years) were 
included into the study with 230 samples. Among the 
samples, 65 malignant tissue samples were chosen for 
IHC test. 
PTEN expression rate in malignant breast tissue was 
50.8% of the cases (33 out of 65 samples). As shown in 
table 1, in our study, lack of PTEN expression had a 
significant correlation with involvement of the lymph 
node sent by the sample, vascular or perineural invasion, 
metastasis and chemotherapy background, spontaneous 
malignancy presence, familial history, negative 
progesterone receptor, negative estrogen receptor, and 
positive her2/neu. In our study, no relationship was 
observed between the expression of PTEN with patients’ 
age, tumor size, age group of the patients after 
categorization into two groups of under 50 years and 
over 50 years, lesion location (left or right breast), and 
tumor grade (Table 2). 
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Table 1. Relation between PTEN expression and clinicopathologic features 
Variables Levels 
Total PTEN negative PTEN positive 
P-value 
Count (%) Count (%) Count (%) 
Age group < 50 32 (100) 16 (50) 16 (50) 1.0000 
> 50 33 (100) 16 (48.5) 17 (51.5) 
Grade 1 6 (100) 4 (66.7) 2 (33.3) 0.5480 
2 32 (100) 14 (43.8) 18 (56.3) 
3 27 (100) 14 (51.9) 13 (48.1) 
Lymph node Positive 35 (100) 32 (91.4) 3 (8.6) < 0.0010 
Negative 30 (100) 0 (0) 30 (100) 
Vascular or perineural Positive 36 (100) 32 (88.9) 4 (11.1) 0.0510 
Negative 2 (100) 0 (0) 29 (100) 
Metastasis Positive 36 (100) 32 (88.9) 4 (11.1) 0.0210 
Negative 29 (100) 0 (0) 2 (100) 
ER, PR Positive 38 (100) 77 (18.4) 31 (81.6) < 0.0010 
Negative 27 (100) 25 (92.6) 2 (7.4) 
Her2/neu Positive 35 (100) 29 (82.9) 6 (17.1) 0.0040 
Negative 30 (100) 3 (10) 27 (90) 
Synchronous malignancy Positive 35 (100) 29 (82.9) 6 (17.1) 0.0450 
Negative 30 (100) 3 (10) 27 (90) 
Family history Positive 35 (100) 31 (88.6) 4 (11.4) 0.0340 
Negative 30 (100) 1 (3.3) 29 (96.7) 
Chemotherapy Positive 32 (100) 29 (90.6) 3 (9.4) 0.0012 
Negative 33 (100) 3 (9.1) 30 (90.9) 
Location Left side 29 (100) 16 (55.2) 13 (44.8) 0.4590 
Right side 36 (100) 16 (44.4) 20 (55.6) 
PTEN: Phosphatase and tensin 
 
Discussion 
PTEN expression in different studies has been reported 
from 48% in Sara’s study to 70% in Golmohammadi et 
al.’s study (12). Gonzalez-Angulo et al. (13) examined 
the role of PTEN in the metastasis of breast cancer. In 
this study, as well as the current study, IHC technique 
was used to study gene expression and the results 
indicated that there was a significant difference 
between PTEN gene expression in metastatic and non-
metastatic samples. In other words, the lack of PTEN 
expression was associated with a higher metastasis that 
this study as well as other mentioned studies is 
consistent with the results of our study. PTEN gene 
plays a role in the development of synchronous 
malignancies; Cowden syndrome can be regarded as a 
good example in this field, as well as in several studies, 
synchronization of ovarian and endometrial cancer 
have been investigated in patients with mutations in 
this gene. For example, Lin et al. (14) have been 
studied the various mutations of PTEN and its relation 
to simultaneous endometrial and ovarian cancer. In our 
study, there was a statistically significant correlation 
between PTEN expression and simultaneous malignancy 
in patients with breast cancer. Of course, this needs to be 
confirmed by prospective and more accurate studies to 
distinguish between metastasis and simultaneous 
malignancy, accurately. In Lee-Hoeflich et al. study 
(15), the expression of PTEN and her2 was investigated 
that its results as of the results of the current study 
indicated that PTEN status in breast cancer is differed 
significantly between her2-positive and her2-negative 
groups. In Yang et al.’s study (16), the loss of PTEN 
function in malignant cases was more than benign 
tumors. In addition, there was an inverse relationship 
between PTEN expression and tumor stage, cell 
malignancy stage, axillary lymph node involvement, 
recurrence, and metastasis. These results are consistent 
with the results of the current study. Limitations such as 
small malignant sample size, defective recording of 
medical documents, and limitation in preparing the 
experiment materials existed in our study.  
 
Table 2. Relation between PTEN with age and size 
Variables Index PTEN positive PTEN negative 
Size Mean ± Standard deviation 3.385 ± 3.530 3.219 ± 2.420 
Count 33 32 
P value 0.826 
Age Mean ± Standard deviation 51.515 ± 13.650 51.656 ± 13.460 
Count 33 32 
P value 0.967 
PTEN: Phosphatase and tensin 
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Disaffiliation between PTEN and patients’ age, 
tumor size, age group of the patients after 
categorization into two groups of under 50 years and 
over 50 years, lesion location (left or right breast), and 
tumor grade could be due to the following reasons: (1) 
difference in sample size, (2) difference in agreed 
percent for confirming positivity of these markers 
expression, (3) difference in technique and method of 
performing IHC, and (4) applying different 
classifications for clinicopathologic index. 
Although the current study is subject to some 
limitations, its results identify PTEN loss as a frequent 
event in breast cancer that is closely associated with 
progression and poor prognosis. PTEN may be a 
promising, useful biomarker for predicting clinical 
outcomes in women with breast cancer. 
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